Association of Nonsteroidal Anti-inflammatory Drug Use With Survival in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Chemoradiation Therapy

Iovoli, Austin J.; Hermann, Gregory M.; Jun, Sung; Platek, A.; Farrugia, Mark; Yau, Edwin; Wooten, Kimberly; Arshad, Hassan; Gupta, Vishal; Kuriakose, Moni Abraham; Hicks, Wesley L.; Singh, Anurag

doi:10.1001/jamanetworkopen.2020.7199

Cited by 15 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, as reported earlier, poor treatment outcome observed in the HNSCC cases with CYP2A6 variants could also be partly attributed to the altered metabolism of drugs (nonsteroidal anti-inflammatory drugs) used along with the chemotherapeutic drugs or during CT/RT (Iovoli et al, 2020;Jeong et al, 2017). Further evidence that CYP2A6 polymorphism leads to poor treatment outcomes was provided by our data indicating poor survival of HNSCC cases with deletion or reduced activity genotype.…”

Section: Discussionsupporting

confidence: 81%

Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome

Yadav

Katiyar

Ruwali

et al. 2021

Environ and Mol Mutagen

View full text Add to dashboard Cite

The present case-control study consisting of 1300 cases of head and neck squamous cell carcinoma (HNSCC) and the equal number of controls aimed to investigate the association of functionally important polymorphisms in cytochrome P4502A6 (CYP2A6*1B, CYP2A6*4C, CYP2A6*9-rs28399433) with HNSCC and the treatment response in cases receiving a combination of chemotherapy/radiotherapy (CT/RT). A significant decrease in risk to HNSCC was observed in the cases with deletion (CYP2A6*4B and CYP2A6*4C) or reduced activity genotypes (CYP2A6*9) of CYP2A6. This risk to HNSCC was further reduced significantly in tobacco users among the cases when compared to nontobacco users among the cases. The risk was also reduced to a slightly greater extent in alcohol users among the cases when compared to nonalcohol users among the cases. In contrast with decreased risk to HNSCC, almost half of the cases with variant genotypes of CYP2A6 (CYP2A6*1A/*4C+*1B/*4C+*4C/*4C and *9/*9) did not respond to the treatment. Likewise, the survival rate in cases receiving the treatment, after 55 months of follow-up was significantly lower in cases with deletion (6.3%) or reduced activity (11.9%) allele than in the cases with common alleles (41%). The present study has shown that CYP2A6 polymorphism significantly reduces the risk to HNSCC. Our data further suggested that CYP2A6 polymorphism may worsen the treatment outcome in the cases receiving CT/RT.

show abstract

Section: Discussionsupporting

confidence: 81%

Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome

Yadav

Katiyar

Ruwali

et al. 2021

Environ and Mol Mutagen

View full text Add to dashboard Cite

show abstract

“…As this study required baseline and post-treatment HRQOL measures, many patients from prior analyses were excluded. As such, the study population is relatively smaller and the follow-up is limited, therefore, many variables found to influence the outcome of HNC patients in prior reports were not significant in the current investigation [ 28 , 29 , 35 ]. This can be a common challenge when investigating HRQOL measures.…”

Section: Discussionmentioning

confidence: 79%

A Principal Component of Quality of Life Measures Is Associated with Survival for Head and Neck Cancer Patients Treated with Radiation Therapy

Farrugia

Jun

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Health-related quality of life (HRQOL) metrics can be associated with survival in head and neck cancer (HNC); however, the impact of HRQOL recovery and the relevant HRQOL domains regarding outcome are unclear. Methods: Using a single-institution database, we retrospectively reviewed HNC patients treated with definitive or postoperative radiation therapy between 2013 and 2018. The recovery of individual HRQOL domains were determined by the ratio of the post-treatment to baseline scores. Univariate and Multivariate Cox regression were used to analyze survival outcomes. Principal component analysis was used to adjust for multicollinearity of HRQOL domains. Results: In 218 HNC patients who received radiation therapy, median follow-up was 24.8 months (interquartile range (IQR) 14.5–32.0). Principal component analysis evaluating the recovery of HRQOL domains revealed two independent principal components (PC), PC1 and PC2. PC1, which received contributions from the functional domains; physical (PF), role (RF), emotional (EF), cognitive (CF), and global health status (GQOL) was significantly associated with disease-free (HR = 0.77, 95% CI 0.61–0.98, p = 0.034) and overall survival (HR = 0.76, 95% CI 0.65–0.91, p = 0.004) on multivariate analysis and PC2, had no correlation with outcome and was mainly represented by social functioning. Unplanned hospitalization was significantly associated with lower PC1 scores (β = −0.997, Std. Error = 0.244, p < 0.001). Conclusion: Our study provides evidence that post-treatment recovery of HRQOL domains were associated with overall survival (OS) in HNC. PC1 is an attractive clinical tool to assess the recovery across multiple different HRQOL and the relationship with survival. Future prospective studies may identify patients who could benefit from additional rehabilitation based on PC1 score.

show abstract

“…Some studies suggest that aspirin use has bene cial effects on head and neck squamous cell carcinoma (HNSCC) [16][17][18][19] , while other studies do not show this 20,21 . HNSCC is a collective term for carcinoma arising within the anatomic region of the head and neck, including the oral cavity, oropharynx, hypopharynx, nasopharynx and larynx.…”

Section: Discussionmentioning

confidence: 99%

The Beneficial Effect of Low-Dose Aspirin on the Survival of Pathological Advanced-Stage Oral Squamous Cell Carcinoma Patients

Luo

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.

show abstract

Association of Nonsteroidal Anti-inflammatory Drug Use With Survival in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Chemoradiation Therapy

Cited by 15 publications

References 26 publications

Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome

Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome

A Principal Component of Quality of Life Measures Is Associated with Survival for Head and Neck Cancer Patients Treated with Radiation Therapy

The Beneficial Effect of Low-Dose Aspirin on the Survival of Pathological Advanced-Stage Oral Squamous Cell Carcinoma Patients

Contact Info

Product

Resources

About